XML 58 R50.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 26, 2023
Mar. 30, 2023
Jun. 30, 2023
Jun. 30, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disaggregation Of Revenue [Line Items]              
Net product revenue         $ 3,746,000 $ 140,141,000  
Deferred revenue, current portion         1,642,000 1,189,000  
Deferred revenue, long term         1,294,000 2,727,000  
Product Revenue, Net              
Disaggregation Of Revenue [Line Items]              
Net product revenue         0 1,044,000  
GlaxoSmithKline Intellectual Property              
Disaggregation Of Revenue [Line Items]              
Development milestones recevied         10,000,000    
License agreement contract asset         9,500,000 19,300,000  
Exclusive License And Collaboration Agreement              
Disaggregation Of Revenue [Line Items]              
Non refundable upfront payment received             $ 10,000,000
Transaction price         12,100,000    
Fixed upfront cash payment         10,000,000    
Amount related to withholding tax obligations         1,100,000    
Asset Purchase Agreement | Cypralis Limited              
Disaggregation Of Revenue [Line Items]              
Revenue recognized         0 0  
License Agreement | Waterstone Pharmaceutical HK Limited              
Disaggregation Of Revenue [Line Items]              
Revenue recognized         0 0  
License Agreement | GlaxoSmithKline Intellectual Property              
Disaggregation Of Revenue [Line Items]              
Success-based development milestones receivable       $ 45,000,000      
Development milestones recevied     $ 25,000,000        
Revenue recognized           4,400,000  
Non refundable upfront payment received   $ 90,000,000          
Total transaction price       136,100,000      
Payment of transaction price       90,000,000      
License transfer performance obligation revenue       130,100,000      
Research and development activity       4,800,000      
Ongoing clinical and preclinical studies       $ 1,200,000      
Unbilled receivable           4,400,000  
License Agreement | GlaxoSmithKline Intellectual Property | License Transfer              
Disaggregation Of Revenue [Line Items]              
Revenue recognized         1,100,000 $ 1,700,000  
Achivement of Threshold Upto 200 Million | License Agreement | GlaxoSmithKline Intellectual Property              
Disaggregation Of Revenue [Line Items]              
Sales milestone payable upon achievement of threshold limit   77,500,000          
Achivement of Threshold Upto 200 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date One              
Disaggregation Of Revenue [Line Items]              
Sales milestone payable upon achievement of threshold limit $ 64,000,000            
Achivement of Threshold Upto 200 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Two              
Disaggregation Of Revenue [Line Items]              
Sales milestone payable upon achievement of threshold limit 54,250,000            
Achivement of Threshold Upto 200 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Three              
Disaggregation Of Revenue [Line Items]              
Sales milestone payable upon achievement of threshold limit 46,500,000            
Achivement of Threshold Upto 300 million to 500 Million | License Agreement | GlaxoSmithKline Intellectual Property              
Disaggregation Of Revenue [Line Items]              
Sales milestone payable upon achievement of threshold limit   65,000,000          
Achivement of Threshold Upto 300 million to 500 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date One              
Disaggregation Of Revenue [Line Items]              
Sales milestone payable upon achievement of threshold limit 45,500,000            
Achivement of Threshold Upto 300 million to 500 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Two              
Disaggregation Of Revenue [Line Items]              
Sales milestone payable upon achievement of threshold limit 45,500,000            
Achivement of Threshold Upto 300 million to 500 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Three              
Disaggregation Of Revenue [Line Items]              
Sales milestone payable upon achievement of threshold limit 39,000,000            
Achivement of Threshold Upto 750 million to 1 Billion | License Agreement | GlaxoSmithKline Intellectual Property              
Disaggregation Of Revenue [Line Items]              
Sales milestone payable upon achievement of threshold limit   50,000,000          
Achivement of Threshold Upto 750 million to 1 Billion | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date One              
Disaggregation Of Revenue [Line Items]              
Sales milestone payable upon achievement of threshold limit 35,000,000            
Achivement of Threshold Upto 750 million to 1 Billion | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Two              
Disaggregation Of Revenue [Line Items]              
Sales milestone payable upon achievement of threshold limit 35,000,000            
Achivement of Threshold Upto 750 million to 1 Billion | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Three              
Disaggregation Of Revenue [Line Items]              
Sales milestone payable upon achievement of threshold limit 30,000,000            
Completion FURI, CARES, and NATURE Clinical Studies | License Agreement              
Disaggregation Of Revenue [Line Items]              
Development milestones recevied 10,000,000            
Successful Completion of Mario Study | License Agreement | GlaxoSmithKline Intellectual Property              
Disaggregation Of Revenue [Line Items]              
Development milestones recevied 7,350,000            
Maximum | Exclusive License And Collaboration Agreement              
Disaggregation Of Revenue [Line Items]              
Potential development and commercial milestones yet to receive         $ 110,000,000    
Maximum | License Agreement | GlaxoSmithKline Intellectual Property              
Disaggregation Of Revenue [Line Items]              
Regulatory milestone payments receivable 49,000,000 70,000,000          
Commercial milestones payments receivable 57,500,000 115,000,000          
Sales milestone payments receivable   242,500,000          
Development milestones receivable 72,350,000 $ 75,500,000          
Maximum | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date One              
Disaggregation Of Revenue [Line Items]              
Sales milestone payments receivable 179,500,000            
Maximum | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Two              
Disaggregation Of Revenue [Line Items]              
Sales milestone payments receivable 169,750,000            
Maximum | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Three              
Disaggregation Of Revenue [Line Items]              
Sales milestone payments receivable 145,500,000            
Maximum | Achivement of Two Interim Milestone of Ongoing Mario Study | License Agreement | GlaxoSmithKline Intellectual Property              
Disaggregation Of Revenue [Line Items]              
Development milestones receivable $ 30,000,000            
Sales Revenue Net | Customer Concentration Risk | Wholesaler One              
Disaggregation Of Revenue [Line Items]              
Percentage of gross revenue           44.00%  
Sales Revenue Net | Customer Concentration Risk | Wholesaler Two              
Disaggregation Of Revenue [Line Items]              
Percentage of gross revenue           28.00%  
Sales Revenue Net | Customer Concentration Risk | Wholesaler Three              
Disaggregation Of Revenue [Line Items]              
Percentage of gross revenue           26.00%